Loading... Please wait.
Company profile
Sensorion is a clinical-stage biotech company, that specializes in the development of novel therapies to restore, treat and prevent hearing loss disorders, a significant global unmet medical need.
Sensorion has built a R&D technology platform to expand its understanding of the pathophysiology and etiology of inner ear related diseases, enabling it to select the best targets and modalities for drug candidates.
Its clinical-stage portfolio includes one Phase 2 product: SENS-401 (Arazasetron) progressing in a proof of concept (PoC) clinical study in cisplatin-induced ototoxicity (CIO) and, with partner Cochlear Ltd, in a study in patients scheduled for cochlear implantation.
Sensorion has entered into a strategic collaboration with Institut Pasteur. It has two gene therapy programs, at preclinical stage, aimed at correcting hereditary forms of deafness including deafness caused by a mutation of the gene encoding for Otoferlin, and hearing loss related to mutation in GJB2 gene.
Source:
Cofisem
-
Last Update:
03 Apr 2025
Key Executives
| Chief Executive Officer | Nawal Ouzren | ||||
| Head of Investor Relations | Noémie Djokovic | ||||
| Source: Cofisem - Last Update: 03 Apr 2025 | |||||
Key figures
| Millenium | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Net sales | 0 | 0 | 0 | 0 | 0 |
| Income from ordinary activities | 0 | 0 | 0 | 0 | 0 |
| Operating income | -28.401 | -22.310 | -23.137 | -15.025 | -8.889 |
| Cost of financial indebtedness net | 251 | 109 | 0 | 89 | |
| Equity-accounted companies contribution to income | |||||
| Net profit from discontinued activities | |||||
| Net income | -25.972 | -22.063 | -23.209 | -15.137 | -8.978 |
| Net income (Group share) | -25.972 | -22.063 | -23.209 | -15.137 | -8.978 |
| Fiscal year end | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
| Length of fiscal year (month) | 12 | 12 | 12 | 12 | 12 |
| Currency & Unit | EUR - thousands | EUR - thousands | EUR - thousands | EUR - thousands | EUR - thousands |
| Account Standards | IFRS | IFRS | IFRS | IFRS | IFRS |
| Source: Cofisem - Last Update: 03 Apr 2025 | |||||
Shareholder information
Address
Sensorion
375 Rue du Professeur Joseph Blayac
FR-34080
Montpellier
France
Phone number:
+33 (0)4 67 20 77 30
Fax:
+33 (0)4 99 54 58 84
Source:
Cofisem
-
Last Update:
03 Apr 2025
Contact
Source: Sensorion - Last Update: 03 Apr 2025